1,096 results on '"Sampson, John H"'
Search Results
152. CAR T cells and checkpoint inhibition for the treatment of glioblastoma
153. Current multidisciplinary management of brain metastases
154. Comparative study of α-helical and β-sheet self-assembled peptide nanofiber vaccine platforms: influence of integrated T-cell epitopes
155. Brain immunology and immunotherapy in brain tumours
156. The Evolving Modern Management of Brain Metastasis
157. Cryptococcal meningitis in patients with glioma: a report of two cases
158. EGFRvIII-Targeted Vaccination Therapy of Malignant Glioma
159. A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas
160. Brain Metastases from Malignant Melanoma
161. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma
162. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma
163. Immunotherapy of malignant brain tumors
164. Viruses in the treatment of malignant glioma
165. Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme
166. Phase I Trial of Temozolomide Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma
167. Surgical Management of Petroclival Meningiomas: Defining Resection Goals Based on Risk of Neurological Morbidity and Tumor Recurrence Rates in 137 Patients
168. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the 'immunologically privileged' central nervous system
169. How does the immune system attack cancer?
170. Microvascular Decompression for Glossopharyngeal Neuralgia: Long-term Effectiveness and Complication Avoidance
171. Phase II Trial of Gefitinib in Recurrent Glioblastoma
172. Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma
173. Phase II Trial of Carmustine Plus O6-Benzylguanine for Patients With Nitrosourea-Resistant Recurrent or Progressive Malignant Glioma
174. Phase II Trial of Murine 131I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas
175. Dendritic Cells Pulsed with a Tumor-specific Peptide Induce Long-lasting Immunity and Are Effective against Murine Intracerebral Melanoma
176. The current state of immunotherapy for gliomas: an eye toward the future
177. Brain Tumor Microenvironment and Host State: Implications for Immunotherapy
178. Pharmacokinetic Analysis of a Novel Human EGFRvIII:CD3 Bispecific Antibody in Plasma and Whole Blood Using a High-Resolution Targeted Mass Spectrometry Approach
179. MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation
180. Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.
181. MDNA55: A locally administered IL4 guided toxin as a targeted treatment for recurrent glioblastoma.
182. Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.
183. Monocytes outperform ex vivo generated dendritic cells as cellular vaccines to trigger cytotoxic T lymphocyte responses against cancer in pre-clinical models
184. Effective effectors: How T cells access and infiltrate the central nervous system
185. Immunotherapy for Glioblastoma: Adoptive T-cell Strategies
186. The effect of adoptive transfer of ex vivo activated T cells on the efficacy and tumor penetrance of intravenously-administered CD3-engaging bispecific antibody.
187. Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice
188. Author Correction: Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors
189. Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts
190. Institutional Review of Mortality in 5434 Consecutive Neurosurgery Patients
191. Characterization of a Spontaneous Murine Astrocytoma and Abrogation of Its Tumorigenicity by Cytokine Secretion
192. Accuracy of Novel Computed Tomography–Guided Frameless Stereotactic Drilling and Catheter System in Human Cadavers
193. Glomus Jugulare Tumor Metastatic to the Sacrum after High-dose Radiation Therapy: Case Report
194. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma
195. The current state of immunotherapy for gliomas: an eye toward the future.
196. CD27 stimulation unveils the efficacy of linked class I/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4/CD8 T cell response
197. A simple and enzyme-free method for processing infiltrating lymphocytes from small mouse tumors for ELISpot analysis
198. A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma
199. Recurrent Glioblastoma Treated with Recombinant Poliovirus
200. Introduction. Update on adult neuro-oncology
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.